Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

ion with the exits of these facilities, the Company recorded $10.7 million of non-cash lease termination exit costs.

Interest ExpenseInterest expense of $5.0 million for the second quarter 2011 primarily relates to the 4.0% convertible senior notes due 2016 issued in August 2009 and includes non-cash imputed interest expense of $4.9 million as a result of the application of ASC 470-20.

Cash, Cash Equivalents and Marketable SecuritiesOn June 30, 2011, cash, cash equivalents, and current and non-current marketable securities were $550.6 million compared to $577.9 million at December 31, 2010. This excludes restricted cash of $31.9 million at December 31, 2010.  

Six-Month ResultsNexavar net sales, as recorded by Bayer, were $481.1 million and $450.5 million for the six months ended June 30, 2011 and 2010, respectively. Non-GAAP net loss for the six months ended June 30, 2011 was $41.4 million, or $0.66 per diluted share, compared to non-GAAP net income of $1.4 million, or $0.02 per diluted share for the same period in 2010. Non-GAAP net income excludes employee stock-based compensation expense, non-cash imputed interest expense related to the application of ASC Subtopic 470-20, non-cash items related to the advance funding and impairment of equity investment in S*BIO, lease termination exit costs  and adjustments to contingent consideration expense in connection with our acquisition of Proteolix. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)." For the six months ended June 30, 2011, on a GAAP basis Onyx recorded a net loss of $103.7 million, or $1.64 per diluted share, compared with a net loss of $109.2 million, or $1.75 per diluted share, for the same period in 2010.

Management Conference Call TodayOnyx will host a webcast and teleconference with management to discuss second quarter 2011 fi
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
4. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
5. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
6. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... By Dennis Thompson HealthDay ... and bisexual men who have abstained from sex for one year ... a new federal policy that would reverse a 31-year ban on ... Food and Drug Administration announced Tuesday its intention to release a ... door to blood donations from gay men. The FDA is ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay ... -- Teens are more likely to start smoking or ... hyperactivity disorder (ADHD) or conduct disorder, new research ... families about the risk of substance use as [these] ... research director at Cincinnati Pediatric Research Group, which is ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... Ann Karmanos Cancer Institute and Karmanos Cancer Center ... Ann G. Schwartz, Ph.D. has been appointed Interim ... has been appointed Interim Chief Operating Officer.(Logo: ... to lead us during this period of transition," ...
... 5 Change to Win chair Anna ... House Forum on Health Reform, which was attended by various ... as a nation that are as complex and consequential as ... their health coverage every day, we can no longer turn ...
... The Pennsylvania Breast Cancer Coalition and the Pennsylvania Association of ... sign up for the 2nd annual Home Run Derby EPHRATA, ... out your baseball bat and head out to the ballpark! ... of Community Bankers have joined together once again to bring ...
... International, LLC officially kicks off "Sleep Better America," ... campaign, with the launch of http://www.sleepbetteramerica.net . ... consumers about sleep-related issues with timely information, tools, ... studies.The "Sleep Better America" Web site centralizes unique ...
... The medication patches should be removed ahead of time, ... The U.S. Food and Drug Administration warned Thursday that ... while patients undergo an MRI. , Thursday,s warning applies ... over-the-counter -- including nicotine and pain-control patches. , Some ...
... suggests that the standard treatment for a common brain ... leaving patients more vulnerable to tumor recurrence. The research, ... of the journal Cell Stem Cell , provides ... stem-like cells to escape cytotoxic treatment and repopulate the ...
Cached Medicine News:Health News:Karmanos Cancer Institute Announces Interim Leadership 2Health News:Karmanos Cancer Institute Announces Interim Leadership 3Health News:Change to Win Statement on White House Health Care Forum 2Health News:Take A Swing Against Breast Cancer! 2Health News:AmericInn Hotels Kicks-Off 'Sleep Better America' With Launch of New Web Site to Educate Consumers About Insomnia and Sleep-Related Issues 2Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Brain tumor treatment may increase number of cancer stem-like cells 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: